Unlock instant, AI-driven research and patent intelligence for your innovation.

Method of treating endotoxemia

A technology of endotoxemia and endotoxin, applied in gene therapy, biochemical equipment and methods, viruses, etc., can solve the problem of low responsiveness

Inactive Publication Date: 2005-08-10
TEMPLE UNIVERSITY
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This mouse line is less responsive to the immunostimulatory and pathophysiological effects of the lipid A component of LPS, and it is therefore believed to have a fundamental defect in its response to LPS compared with a closely related responsive mouse line

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating endotoxemia
  • Method of treating endotoxemia
  • Method of treating endotoxemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] C3H / HeJ mouse Lps d Isolation and identification of genes

[0064] Studies by Kang et al. (Infection and Immunity, 64, 4612-4617 (1996)) showed that Lps n Gene restores lipopolysaccharide-mediated B cell responses in splenic B cells of C3H / HeJ mice.

[0065] To confirm that the Lps gene is defective in the genome of C3H / HeJ mice, and this defect leads to low responsiveness to LPS stimulation, the Lps gene was isolated from the cDNA library of pCD-HeJ.

[0066] RNA from C3H / HeJ splenic B cells was used to construct an Okayama-Berg cDNA expression library (Okayama, H. and Berg, P. et al., Mol. Cell Biol., 2, 161-170 (1982)). Spread the pCD-HeJ cDNA library on 8 flat plates (5.8×10 4 clones), with the Lps of LPS responder mouse C3H / HeOuJ n The library was probed with a 0.9 kb BamHI-PstI fragment in the cDNA (Infection and Immunity, 64, 4612-4617 (1996)). 25 positive clones were identified.

[0067] Of the 25 independent clones analyzed, 8 were full-length cDNAs, as ...

Embodiment 2

[0072] Lps n and Lps d Construction of retroviral vectors

[0073] The Lps of embodiment 1 n and Lps d The cDNA was cloned into the XhoI site of the N2 retroviral vector (Wong et al., Molecular Cell Biology, 9, 798-808 (1989); Wong et al., Genes Dev. 1, 358-365 (1987)). The N2 retroviral vector includes 5' and 3' MMLV LTRs, splice donor and splice acceptor sites, and a neomycin resistance marker gene.

[0074] Will Lps n cNDA was isolated from the XhoI restriction fragment of pCD-LPS (Infection and Immunity, 64, 4612-4617 (1996)) and ligated into the site of the XhoI restriction fragment of the N2 retroviral vector to generate pN2-Lps n . Use the same method to generate pN2-Lps d vector, except that the mutant LPS used d cDNA.

[0075] To generate carrying Lps n and Lps d Retroviral stocks of sequences, respectively, with pN2-Lps n and pN2-Lps d The plasmid DNA was transfected into GP / E virus packaging cells by calcium phosphate DNA co-precipitation method (Mar...

Embodiment 3

[0079] Lps n and Lps dGene transfer into splenic B cells of C3H / HeJ mice via retrovirus

[0080] A) Retroviral gene transfer

[0081] Splenic B cells from C3H / HeJ mice were depleted of red blood cells, retrovirally infected in the presence of 100 μg / ml LPS, and cultured in S17 mesenchymal cell conditioned medium (known to stimulate pre-B cell growth) (Collins et al., Journal of Immunology, 138, 1082-1087 (1987); Dorshkind et al., Journal of Immunology Methods (J.Immunol.Meathods), 123, 93-101 (1989); Narendran et al., European Journal of Immunology (Eur . J. Immunol.), 22, 1001-1006 (1992)). In order to maximize the infection efficiency of retroviruses, the culture medium was repeatedly refreshed with fresh stock solutions of concentrated viral supernatants, as described in the flowchart in Figure 2. N2 parental vector, N2-Lps n or N2-Lps d The virus titers of the concentrated stock solution of the vector were all normalized to 2×10 6 G418 colonies / ml.

[0082] B) MTT ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a therapeutic agent comprising an Lps gene, which downregulates the transduction of LPS-mediated signals and can therefore be administered in order to treat or prevent the occurrence of endotoxemia.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Application No. 60 / 083,210, filed April 27,1998. [0003] about government funding [0004] The invention described herein was supported in part by grant numbers 1RO1AI39159-01A1 and 1RO1CA70854-01 from the National Institutes of Health (NIH). The federal government has certain rights in this invention. field of invention [0005] The present invention relates to Lps d Applications of genes in the treatment and prevention of endotoxemia. Background of the invention [0006] A)LPS [0007] LPS is a complex macromolecule that comes from the cell walls of some bacteria, some of which can cause enteric fever, dysentery, urinary tract infection and other diseases, and other bacteria are usually parasites in the intestinal tract of animals and humans but are generally not pathogenic. All of these bacteria have the same type of cell wall and are classified as Gram-negati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/09A61K31/711A61K35/76A61K38/00A61K48/00A61P31/00A61P39/02C12N9/16
CPCC12N2799/027C12Y301/05001C12N2799/022C12N9/16A61K48/00A61K38/00A61P17/02A61P31/00A61P39/02
Inventor 彼得·M·C·王
Owner TEMPLE UNIVERSITY